Piodar15 mg

Piodar is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

• Established/approved use: Monotherapy for type 2 diabetes mellitus when diet and exercise alone are inadequate.
• Combination therapy (requires an additional agent): Piodar is also approved for use in combination with metformin, a sulfonylurea, or insulin when the current regimen does not provide adequate glycemic control.
• Guideline-supported adjunct role: Sometimes used as part of multi-drug regimens in insulin-resistant type 2 diabetes, particularly when weight-neutral or insulin-sparing options are limited.
• Off-label (not FDA-approved, used selectively based on clinical judgment): Non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes or prediabetes, based on evidence from clinical trials; this use should only be undertaken under specialist supervision.

Piodar is not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Each tablet contains Pioglitazone (as pioglitazone hydrochloride) in strengths typically available as 15 mg, 30 mg, and 45 mg oral tablets. Combination products pairing Pioglitazone with metformin or a sulfonylurea are also available in some markets; always confirm the exact composition on the product label being dispensed.

Piodar is an oral antidiabetic medicine belonging to the thiazolidinedione (TZD) class, also known as "glitazones" or insulin sensitizers. Unlike sulfonylureas, Piodar does not stimulate insulin secretion from the pancreas; instead it improves the body's response to the insulin it already produces. It is used as part of a comprehensive treatment plan for type 2 diabetes mellitus that includes diet, exercise, and blood glucose monitoring.

Thiazolidinediones (TZDs) — oral antidiabetic agents (insulin sensitizers)

Pioglitazone is a selective agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-γ), a nuclear receptor found in adipose tissue, skeletal muscle, and liver. Activation of PPAR-γ regulates the transcription of insulin-responsive genes involved in glucose production, transport, and utilization.

• Increases peripheral insulin sensitivity in muscle and adipose tissue, enhancing glucose uptake.
• Reduces hepatic glucose output (gluconeogenesis).
• Lowers circulating insulin levels while improving glycemic control, reflecting reduced insulin resistance.
• Has favorable effects on some lipid parameters (may raise HDL-cholesterol and lower triglycerides in some patients), though it is not indicated for dyslipidemia.

Onset of full glycemic effect is gradual; maximal benefit on fasting glucose and HbA1c may take several weeks to a few months of continuous therapy.

Piodar tablets should be swallowed whole with a glass of water, once daily, at approximately the same time each day, with or without food. Do not crush, chew, or split the tablet unless advised by a pharmacist. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped — do not double the dose.

• Insulin and insulin secretagogues (e.g., sulfonylureas): Combined use with Piodar increases the risk of hypoglycemia; dose reduction of the concomitant agent may be needed, and blood glucose should be monitored closely.
• Gemfibrozil: A strong CYP2C8 inhibitor that can substantially increase Piodar plasma concentrations; a lower dose of Piodar and close monitoring are recommended if co-administration is necessary.
• Rifampin and other CYP2C8 inducers: Can significantly decrease Piodar plasma concentrations, potentially reducing glycemic control; dose adjustment of Piodar may be required.
• Hormonal contraceptives: Piodar may reduce plasma concentrations of ethinyl estradiol/norethindrone combinations to a modest degree; consider this when contraceptive efficacy is important.
• Other insulin sensitizers/TZDs: Concurrent use with other thiazolidinediones is not recommended due to overlapping toxicity (fluid retention, heart failure risk).

Common side effects

• Upper respiratory tract infection, headache, sinusitis
• Weight gain
• Mild to moderate peripheral edema (fluid retention)
• Myalgia (muscle pain)
• Mild anemia (dilutional, from fluid retention)

Serious side effects (seek prompt medical attention)

• Signs of new or worsening heart failure — rapid weight gain, swelling, shortness of breath (see Precautions and Warnings)
• Bone fractures, more frequently reported in women, typically involving the hand, foot, or distal limbs
• Signs of liver injury — unusual fatigue, loss of appetite, dark urine, yellowing of the skin or eyes
• Vision changes suggestive of macular edema
• Blood in urine or new urinary symptoms (see Precautions and Warnings regarding bladder cancer risk)

Pregnancy: Data on the use of Piodar in pregnant women are limited. Type 2 diabetes in pregnancy is generally managed with insulin, as it does not cross the placenta and allows tighter control. Piodar should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use in pregnancy or if pregnancy is confirmed or suspected during treatment.

Lactation: It is not known whether Piodar passes into human breast milk; it has been detected in the milk of lactating rats. Because of the potential for adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Piodar, taking into account the importance of the drug to the mother, and only under medical supervision.

Fertility note: Piodar therapy may result in resumption of ovulation in premenopausal anovulatory women with insulin resistance, creating a risk of unintended pregnancy; adequate contraception should be discussed with a physician.

Boxed warning: congestive heart failure

Piodar can cause or worsen congestive heart failure in some patients. After starting Piodar or increasing the dose, patients should be observed for signs and symptoms of heart failure, including rapid weight gain, edema, and dyspnea. Piodar is contraindicated in NYHA Class III/IV heart failure, and caution plus monitoring is warranted at all severities of heart failure. If heart failure develops, it should be managed per standard of care, and discontinuation or dose reduction of Piodar should be considered.

Other important precautions

• Fluid retention/edema: Dose-related; risk increases when combined with insulin, and can contribute to or unmask heart failure.
• Bone fractures: An increased incidence of bone fractures, particularly in women, has been observed with long-term use; bone health should be considered, especially in postmenopausal women.
• Bladder cancer: Some epidemiological data have raised a possible association between prolonged Piodar use (particularly higher cumulative doses over more than one year) and bladder cancer; findings across studies are not fully consistent, and causality has not been firmly established. As a precaution, Piodar should not be used in patients with active bladder cancer, and should be used with caution and clinical judgment in patients with a prior history of bladder cancer. Patients should report blood in the urine, urinary urgency, pain on urination, or back/abdominal pain to their physician promptly.
• Hepatic effects: Although idiosyncratic hepatotoxicity has been mainly associated with an earlier thiazolidinedione that was withdrawn from the market, periodic liver enzyme monitoring is still recommended with Piodar; therapy should not be started in patients with active liver disease and should be stopped if jaundice or significant liver injury is suspected.
• Hypoglycemia: Piodar alone does not typically cause hypoglycemia, but risk rises when combined with insulin or sulfonylureas.
• Macular edema: Rare cases of new-onset or worsening diabetic macular edema have been reported; patients with visual symptoms should be referred for ophthalmologic evaluation.
• Ovulation resumption: See Pregnancy and Lactation for contraception implications in premenopausal women.

Limited data exist on Piodar overdose in humans. If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. Because Piodar itself is unlikely to cause hypoglycemia alone, overdose is more concerning when the drug is used together with insulin or sulfonylureas, where hypoglycemia can occur. Management should be supportive and symptomatic, guided by a physician, including monitoring of blood glucose, cardiac status (for signs of fluid overload/heart failure), and general supportive care as appropriate.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No dose adjustment of Piodar is required based on renal function alone; however, caution is warranted when co-administered with insulin or sulfonylureas due to hypoglycemia risk (see Interactions).
• Hepatic impairment: Not recommended in patients with active liver disease or significantly elevated baseline liver enzymes (see Precautions and Warnings).
• Elderly patients: No specific dose adjustment is mandated by age alone, but elderly patients may be more susceptible to fluid retention, heart failure, and fractures, so initiate at the lower end of the dosing range and monitor closely.
• Pediatric patients: Safety and efficacy of Piodar have not been established in patients under 18 years of age; use is not recommended.
• Women of childbearing potential: See Pregnancy and Lactation regarding resumption of ovulation and contraception.

Piodar is generally used as long-term, ongoing therapy for the chronic management of type 2 diabetes mellitus, alongside diet, exercise, and regular glucose monitoring. There is no fixed treatment duration; continued use is periodically reassessed by the treating physician based on glycemic control (e.g., HbA1c), tolerability, and monitoring for heart failure, liver, bone, and bladder-related safety signals. Treatment should not be stopped abruptly without medical advice, as this may worsen glycemic control.

Thiazolidinediones (TZDs); PPAR-gamma agonists; oral antidiabetic agents (insulin sensitizers)

Pioglitazone acts as a selective agonist at the peroxisome proliferator-activated receptor-gamma (PPAR-γ), altering the transcription of genes that govern glucose and lipid metabolism. This increases insulin sensitivity in muscle and fat tissue and decreases hepatic glucose production, thereby lowering blood glucose without directly stimulating pancreatic insulin secretion.

C (legacy FDA pregnancy category under the older labeling system; current U.S. prescribing information uses the narrative Pregnancy and Lactation Labeling Rule format instead of a letter category)

The safety and efficacy of Piodar have not been established in pediatric patients under 18 years of age. Piodar is therefore not recommended for use in children or adolescents, and type 2 diabetes in this age group should be managed with agents and strategies specifically studied and approved for pediatric use, under specialist care.